Riskpilot← Back to searchSign inGet full accessEskilstuna City Lab AB
ABActiveOrg 5567818785Kungsgatan 39Manufacture of medical and dental instruments and supplies · NACE 3250Est. 20093 employees
Revenue 2025
SEK 2,7M
+10% vs 2024
EBITDA margin
-0.6%
-260% vs 2024
Equity ratio
29.1%
Financial strength
Net profit 2025
SEK 69K
-58% vs 2024
| Revenue | SEK 2,7M | +10% |
| EBITDA | SEK -16K | -260% |
| Net profit | SEK 69K | -58% |
| Total assets | SEK 600K | -20% |
| Equity | SEK 175K | -40% |
| Employees | 3 | — |
Legal name
Eskilstuna City Lab AB
Org number
5567818785
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
4 maj 2009
Share capital
SEK 100 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva tandtekniskt laboratorium samt handel med värdepapper.
Address
Kungsgatan 39
Email
eacitylab@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 815 | 2 441 | 2 465 | 2 483 | 2 733 |
| Staff expenses | — | — | −1 138 | −1 415 | −1 576 |
| EBITDA | 500 | 411 | 300 | 10 | −16 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 500 | 411 | 300 | 10 | −16 |
| Net financials | −6 | −4 | −3 | 4 | 1 |
| Profit before tax | 372 | 306 | 222 | 209 | 88 |
| Tax | −80 | −63 | −47 | −46 | −19 |
| Net profit | 292 | 243 | 175 | 163 | 69 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 902 | 943 | 1 002 | 754 | 600 |
| Equity | 392 | 454 | 380 | 293 | 175 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 387 | 265 | 324 | 358 | 425 |
| Total debt | 387 | 265 | 324 | 358 | 425 |
EBITDA margin
-0.6%
This company
15.8%
Market median
-104% vs market
20212025
Equity ratio
29.1%
This company
38.2%
Market median
-24% vs market
20212025
Return on equity
39.6%
This company
18.4%
Market median
+115% vs market
20212025
Net profit margin
2.5%
This company
8.1%
Market median
-69% vs market
20212025
Asset turnover
4.56×
This company
1.12×
Market median
+307% vs market
20212025
Debt / equity
2.43×
This company
0.62×
Market median
-292% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FC Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Eskilstuna City Lab AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fredrik Christer Lundkvist | Chief Executive Officer | 0 companies |
| Pia Ann-Charlotte Sundin | Board of Directors | 0 companies |
| Kent Ingvar Carlsson | Deputy Board Member | 0 companies |
| Gustav Daniel Bragman | Deputy Board Member | 0 companies |